Interleukin-10 and tumor necrosis factor-alpha: model of immunomodulation in multiple sclerosis.

Journal: Neurological Research
Published:
Abstract

Objective: The mechanisms involved in the pathogenesis of relapsing-remitting multiple sclerosis are still unclear. The aim of the present study was to evaluate both cerebrospinal fluid (CSF) CD4+ CD7+ T cells and peripheral blood (PB) interleukin-10 (IL-10) as well as tumor necrosis-alpha (TNF-alpha) levels in patients with definite multiple sclerosis of the relapsing-remitting type.

Methods: To assess the above-mentioned cytokine levels we performed our test by the means of ELI-spot assay; the T-helper cell subset was assayed using flow cytometry.

Results: PB IL-10 levels of multiple sclerosis (MS) patients in remission were significantly (p<0.001) higher than in MS patients in the active phase. There was significant and increased evidence of TNF-alpha levels only in the MS patients in the active phase. CD4+ CD7+ T cells, characterized by a preferential Th1-like cytokine profile, were detectable only in seven patients in the active phase without evidence of a statistical significance with respect to cytokine levels.

Conclusions: The data indicate that the production of different cytokines characterized the expression of relapsing-remitting MS. The data also suggest that is it possible to control MS using the regulatory cytokine balance.

Authors
Oreste Perrella, Costanza Sbreglia, Marco Perrella, Giuliano Spetrini, Fernanda Gorga, Marianna Pezzella, Alessandro Perrella, Luigi Atripaldi, Pietro Carrieri
Relevant Conditions

Necrosis, Multiple Sclerosis (MS)